ATOSSA THERAPEUTICS, INC. Accumulated Other Comprehensive Income
ATOSSA THERAPEUTICS, INC. (ATOS) had Accumulated Other Comprehensive Income of -$54.00 thousand as of 2022-09-30, per its 10-Q filed 2022-11-07.
Discontinued › Balance Sheet › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2022-11-07
- 2022-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$54.00K.
- 2021-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $0.00.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2022-09-30 | -$54.00K 10-Q · filed 2022-11-07 |
| 2021-12-31 | $0.00 10-Q · filed 2022-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |